Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder

Completed · Phase 3 · Has a placebo group

Conditions studied: Anxiety Disorders, Somatoform Disorders

In brief

This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.

Key facts

Study ID

NCT00149799

Run by

Massachusetts General Hospital

People needed

100

Starts

2005-05-01

Expected to finish

2013-03-01

Last updated by the study team

2017-12-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatient men and women age 18 and older
• Diagnosis of BDD within 6 months of study start date based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
• Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale
• Lives within driving distance of Boston, MA or Providence, RI

You may not qualify if…

• Suicidal or homicidal tendencies
• Alcohol/drug abuse or dependence within 3 months of study entry

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• Rhode Island Hospital — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.